ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 2806
A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
9:00AM-11:00AM
Abstract Number: 2829
Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2851
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
9:00AM-11:00AM
Abstract Number: 2841
Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2847
Antibodies to Double Stranded DNA:  Combined Standard ELISA and High-Salt ELISA Assays for the Detection of SLE Disease Activity
9:00AM-11:00AM
Abstract Number: 2845
Antineutrophil Cytoplasmic Antibodies in Systemic Lupus Erythematosus: Incidence, Outcome and Prognosis
9:00AM-11:00AM
Abstract Number: 2846
Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility
9:00AM-11:00AM
Abstract Number: 2840
Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
9:00AM-11:00AM
Abstract Number: 2831
Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2816
Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature
9:00AM-11:00AM
Abstract Number: 2800
Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2850
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2839
Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in  Systemic Lupus Erythematosus (SLE) Patients
9:00AM-11:00AM
Abstract Number: 2812
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
9:00AM-11:00AM
Abstract Number: 2819
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
9:00AM-11:00AM
Abstract Number: 2826
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
9:00AM-11:00AM
Abstract Number: 2809
Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories
9:00AM-11:00AM
Abstract Number: 2803
Comparison of Clinical and Serological Differences According to the Autoantibody Cluster in Women with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry
9:00AM-11:00AM
Abstract Number: 2815
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
9:00AM-11:00AM
Abstract Number: 2802
Comparison of the Clinical, Serological, and Prognostic Differences Among Juvenile-, Adult-, and Late-Onset Lupus Nephritis in Korean Patients: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 2820
Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2810
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
9:00AM-11:00AM
Abstract Number: 2828
Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up
9:00AM-11:00AM
Abstract Number: 2795
Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
9:00AM-11:00AM
Abstract Number: 2818
High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE
9:00AM-11:00AM
Abstract Number: 2838
Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort
9:00AM-11:00AM
Abstract Number: 2792
Hyperhomocysteinemia in SLE
9:00AM-11:00AM
Abstract Number: 2817
Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers
9:00AM-11:00AM
Abstract Number: 2814
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2844
Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2837
Importance of Mixed Speckled/ Homogeneous DFS70 ANA Patterns
9:00AM-11:00AM
Abstract Number: 2821
Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?
9:00AM-11:00AM
Abstract Number: 2854
Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
9:00AM-11:00AM
Abstract Number: 2824
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
9:00AM-11:00AM
Abstract Number: 2852
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
9:00AM-11:00AM
Abstract Number: 2835
Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2833
Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE
9:00AM-11:00AM
Abstract Number: 2796
Low Versus High Dose Glucocorticosteroid Used in Lupus Nephritis:  Is There a Difference
9:00AM-11:00AM
Abstract Number: 2836
Microparticles of Endothelial  Origin in  Women with   Systemic LUPUS Erythematosus UNDER Treatment
9:00AM-11:00AM
Abstract Number: 2798
Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2848
Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
9:00AM-11:00AM
Abstract Number: 2853
Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity
9:00AM-11:00AM
Abstract Number: 2830
Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2832
Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2799
Outcomes in Patients with Early and Delayed Onset Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2805
Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
9:00AM-11:00AM
Abstract Number: 2842
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2801
Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2811
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
9:00AM-11:00AM
Abstract Number: 2804
Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
9:00AM-11:00AM
Abstract Number: 2843
Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2827
Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death
9:00AM-11:00AM
Abstract Number: 2797
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2857
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
9:00AM-11:00AM
Abstract Number: 2813
Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
9:00AM-11:00AM
Abstract Number: 2808
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2822
Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
9:00AM-11:00AM
Abstract Number: 2856
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
9:00AM-11:00AM
Abstract Number: 2807
Skin and Muscle Sodium Concentrations in Patients with Systemic Lupus Erythematosus: A Proof of Concept Study
9:00AM-11:00AM
Abstract Number: 2794
Sustained Complete Remission in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2849
Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations
9:00AM-11:00AM
Abstract Number: 2855
The Long-Term Clinical Outcomes of Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2793
The Predictors of Sustained Complete Remission in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2823
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2825
Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2858
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 2834
Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology